L. Fischer

Most-cited papers

1. Increasing tumor length is associated with regional lymph node metastases and decreased survival in esophageal cancer.

   Kelly R. Haisley, Kyle D. Hart, L. Fischer, Nicholas R. Kunio +6 more

   2016American Journal of Surgery21 citations

   Semantic Scholar

   Save

2. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

   L. Fischer, S. Stintzing, L. V. von Weikersthal, D. Modest +22 more

   2022British Journal of Cancer16 citations Open access

   Semantic Scholar

   Save

3. Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy

   Kathrin Heinrich, L. Fischer, E. de Toni, D. Markwardt +10 more

   2023JCO Precision Oncology8 citations Open access

   Semantic Scholar

   Save

4. Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

   A. Alig, V. Heinemann, M. Geissler, Ludwig Fischer von Weikersthal +15 more

   2022Cancers5 citations Open access

   Semantic Scholar

   Save

5. Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers

   L. Fischer, S. Stintzing, V. Heinemann, U. Keilholz +11 more

   2022Frontiers in Oncology4 citations Open access

   Semantic Scholar

   Save

6. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE‐3)

   A. Stahler, V. Heinemann, J. Holch, Jobst Christian Einem +16 more

   2021International Journal of Cancer4 citations Open access

   Semantic Scholar

   Save

7. Genistein suppresses gallbladder cancer tumorigenesis and progression via downregulating ERBB2 mediated PTK6/AKT/MCM pathway.

   Zhi-Jun Zhou, L. Fischer, B. Edil, Min Li

   2022Science Bulletin2 citations

   Semantic Scholar

   Save

8. SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group

   L. Weiss, V. Heinemann, L. Fischer, F. Gieseler +15 more

   2023Annals of Oncology0 citations Open access

   Semantic Scholar

   Save

9. Impact of exact segment by segment primary tumor location status on anti-EGFR antibody first-line treatment efficacy in RAS/BRAF wild-type and BRAF mutant metastatic colorectal cancer. A pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

   A. Alig, V. Heinemann, M. Geissler, L. V. von Weikersthal +16 more

   20210 citations Open access

   Semantic Scholar

   Save

10. Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110).

    A. Stahler, V. Heinemann, V. Schuster, A. Alig +16 more

    20210 citations

    Semantic Scholar

    Save

11. Abstract B84: Physiologic pancreatic cancer imaging using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)

    L. Fischer, M. Schabel, B. Foster, Charles R. Jr Thomas +3 more

    20160 citations

    Semantic Scholar

    Save